Annapolis, MD—The Plasma Protein Therapeutics Association (PPTA) and its member companies, the major collectors of human plasma and manufacturers of plasma protein therapies will hold their annual PPTA Business Forum in Denver on October 13. The meeting coincides with a kickoff celebration for International Plasma Awareness Week (IPAW), October 13-20, a new global awareness event designed to:
Annapolis, MD—The Plasma Protein Therapeutics Association (PPTA) and its member companies are sponsoring International Plasma Awareness Week, October 13-20, designed to:
Brussels, Belgium—The Plasma Protein Therapeutics Association (PPTA), together with Pharmig and IG Plasma are sponsoring a workshop as part of International Plasma Awareness Week, October 13-20. This event is a joint initiative of PPTA and its member companies designed to:
Annapolis, MD—The Plasma Protein Therapeutics Association (PPTA) and its member companies are sponsoring International Plasma Awareness Week, October 13-20. This inaugural event is designed to:
Annapolis, MD--The first ever International Plasma Awareness Week (IPAW) will be celebrated October 13-20. A joint initiative of the Plasma Protein Therapeutics Association (PPTA) and its member companies, IPAW is designed to:
Mary Gustafson, PPTA Vice President, Global Regulatory Policy, was honored on July 24 with the 2013 FDA Distinguished Alumni Award at the FDA Honor Awards Ceremony, “for exceptional contributions to the regulation of blood and blood products, and as an outstanding liaison between FDA and the plasma protein industry.”
ANNAPOLIS, MD—The Plasma Protein Therapeutics Association (PPTA) opposes New Jersey Senate Bill 2132 that imposes a new tax on therapies used to treat bleeding disorders such as hemophilia.
The Plasma Protein Therapeutics Association is pleased to announce substantive improvements to its Quality Standards for Excellence and Leadership (QSEAL)
The 2013 Plasma Protein Forum was held in Reston, Virginia on June 11-12.
The Plasma Protein Therapeutics Association (PPTA) commends the Preserving Access to Orphan Drugs Acts, bipartisan legislation that makes an important policy clarification and will remove a barrier to research and development of rare disease therapies.
